Blood Cancers | Tumor

A Veteran Reflects on CAR T-Cell Therapy and Isolation

June 27th 2025, 8:00pm

Video

Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.

CAR T Transforms Treatment Landscape for Blood Cancers

June 27th 2025, 3:00pm

Article

CAR T-cell therapy may cure up to 40% of patients with lymphoma and is an option for those who can’t receive transplants, says Dr. André Goy.

What Patients Should Know About Living With WM and the Road Ahead

June 24th 2025, 8:00pm

Video

Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.

Iopofosine-131 Earns FDA Breakthrough for Waldenstrom Macroglobulinemia

June 5th 2025, 3:07pm

Article

Iopofosine-131 received FDA breakthrough status for relapsed or refractory Waldenstrom macroglobulinemia, showing strong response rates in early trials.

Improving Education and Advocacy in Waldenström Macroglobulinemia

May 27th 2025, 7:00pm

Article

Education and patient advocacy are essential to improving care in Waldenström macroglobulinemia amid clinical advances, according to Dr. Shirley D'Sa.

Breaking Down the Stigma and How to Better Understand Rare Blood Cancers

May 1st 2025, 8:00pm

Video

Dr. Neha Mehta-Shah discusses ways patients with rare blood cancers, such as lymphoma, can better understand their specific subtype of disease.

Understanding the Use of Bispecific Antibodies in Multiple Myeloma

April 4th 2025, 9:00pm

Article

Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles.

The Positivity Trap of Follicular Lymphoma and Cancer

March 31st 2025, 5:00pm

Article

As a lymphoma survivor, I struggle with the positivity trap — sometimes, I just want my fears validated instead of being reassured everything is fine.

Itolizumab Shows Long-Term Treatment Benefits in Acute GVHD

March 27th 2025, 3:00pm

Article

Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant benefits in long-term outcomes.

First Patients Dosed in WU-CART-007 Trial for Blood Cancer Subtypes

March 22nd 2025, 6:00pm

Article

The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.